Browse the evidence

Tirzepatide administered at low doses (≤10 mg) for 6 months produces clinically meaningful weight reduction (mean 11.9%) in non-diabetic adults, achieving outcomes comparable to higher doses used in clinical trials.

If you are starting tirzepatide for weight loss without diabetes, you do not need to reach the maximum dose to see significant results. In real-world use, staying on lower doses (like 5mg) for 6 months still resulted in an average 11.9% body weight reduction, which is clinically meaningful.

Real-world use of semaglutide for weight loss (SEMA-WL) in adults with obesity results in median weight loss of 17% after >5 months of treatment, with nausea and constipation being the most common side effects.

If you have obesity and are considering semaglutide, expect significant weight loss (around 17% after 5+ months) but also common side effects like nausea and constipation. Most users find self-injection manageable, though some prefer a pill. Talk to your doctor about managing side effects and setting realistic expectations.

Survodutide, a dual glucagon and GLP-1 receptor agonist, induces significant weight loss in adults with obesity without type 2 diabetes when administered as a once-weekly subcutaneous injection up-titrated to 3.6 or 6.0 mg alongside lifestyle modifications.

This treatment involves a weekly injection that mimics two natural hormones (GLP-1 and glucagon) to reduce appetite and increase energy burn. It is prescribed for adults with obesity who do not have diabetes. To maximize results, patients must follow a reduced-calorie diet and exercise regularly. The dose starts low and increases slowly to minimize stomach upset, which is a common side effect.

Tirzepatide produces significantly greater monthly and annual weight loss, higher patient satisfaction, and improved quality of life compared to Semaglutide and Liraglutide in a Kuwaiti population.

If you are considering GLP-1 therapy for weight loss in Kuwait, Tirzepatide appears to offer the highest weight loss and satisfaction rates compared to Semaglutide and Liraglutide. Be aware that side effects like belching (Tirzepatide) or anxiety (Liraglutide) may influence your choice, and check government facility availability to manage costs.

Combination therapy of sibutramine (10 mg/d) and topiramate (100 mg/d) produces clinically meaningful weight loss (mean 10.2 kg at 36 months) with a tolerable safety profile in real-world clinical settings.

For individuals with obesity who cannot access newer, expensive medications, the combination of sibutramine (10mg) and topiramate (100mg) offers a cost-effective, clinically significant weight loss solution (approx. 10kg over 3 years). It requires medical supervision to manage potential side effects like increased blood pressure or paresthesia, but offers a viable alternative for long-term management in resource-limited settings.

Survodutide, a glucagon receptor/GLP-1 receptor dual agonist, induces significant body weight reduction in people with obesity and type 2 diabetes (T2D) when administered weekly via subcutaneous injection alongside lifestyle modifications.

If you have obesity and Type 2 Diabetes, standard diet and exercise changes often lead to weight regain. This trial investigates a weekly injection (survodutide) that targets both glucose and fat metabolism pathways. It is designed to be taken alongside a modest calorie deficit (500 kcal/day) and 150 minutes of weekly exercise. The dose is slowly increased to minimize stomach side effects, which are common but manageable. This approach aims to provide more durable weight loss than lifestyle changes alone, addressing the specific challenge that T2D can blunt weight loss efforts.

Semaglutide 2.4 mg combined with the WeGoTogether digital support program yields substantial long-term weight loss, with mean percent weight loss reaching -20.4% at 24 months in a real-world setting.

If you have a BMI of 25 or higher, starting semaglutide 2.4 mg and using a digital support app like WeGoTogether can help you lose a significant amount of weight over two years. The app provides reminders, coaching, and tools to help you stay on track. Expect to lose around 20% of your body weight by the end of two years, based on this study's findings.

GCGR-based multi-agonists (mazdutide, pemvidutide, survodutide, retatrutide) produce significantly greater weight loss than existing GLP-1 or GLP-1/GIP therapies by synergistically combining appetite suppression with increased energy expenditure.

If you have obesity and struggle with weight loss despite lifestyle changes, GCGR-based multi-agonists (like mazdutide, retatrutide, etc.) are emerging as highly effective treatments. They work by targeting multiple hormonal pathways to suppress appetite and increase energy expenditure, often resulting in greater weight loss than current GLP-1 drugs. While they are injectable and can cause GI side effects, starting with lower doses and titrating up can help manage these effects. Consult a healthcare provider to see if you are a candidate, especially if you have comorbidities like T2DM or CV disease.

Combining a Very Low-Calorie Ketogenic Diet (VLCKD) with liraglutide produces significantly greater weight loss and metabolic improvements compared to VLCKD alone, primarily through synergistic appetite suppression.

If you are struggling to lose weight with a very low-calorie ketogenic diet alone, adding liraglutide can significantly boost your results. In this study, adding the drug led to nearly 6kg more weight loss over 4 months. Be aware that you are much more likely to experience nausea or constipation, but for most participants, this did not stop them from completing the program. Consult a doctor to see if this combination is safe and appropriate for you, especially given the cost and side effect profile.

Tirzepatide induces rapid, clinically significant weight loss and fat mass reduction within 30 days while preserving fat-free mass in adults with overweight or obesity.

If you are starting tirzepatide for obesity, expect to lose about 4 kg in the first month, mostly from fat stores rather than muscle. This happens even if you are still in the early dose-escalation phase. Adhering to the prescribed lifestyle changes (Mediterranean diet and walking) is part of the protocol, but the drug itself drives significant early fat loss. This rapid initial response can help maintain motivation for long-term treatment.

Treating 50% of moderate- to high-risk obesity patients (Class II and III, excluding diabetes) with 2.4 mg weekly semaglutide plus lifestyle intervention for 68 weeks reduces population prevalence of these obesity classes and yields significant annual societal cost savings.

For healthcare policymakers and insurers, implementing widespread access to 2.4 mg weekly semaglutide for moderate-to-high risk obesity (excluding diabetics) alongside lifestyle programs can significantly reduce the prevalence of severe obesity and save billions in societal costs over time. This requires ensuring affordability and addressing long-term adherence.

GLP-1 receptor agonists and co-agonists induce significant weight loss (10–25%) in adults without diabetes, with newer multi-agonists (e.g., tirzepatide, retatrutide) demonstrating superior efficacy compared to earlier single-agonists.

If you have obesity or overweight with related health issues, GLP-1 medications (like semaglutide or tirzepatide) are now a standard, effective treatment option that can produce significant weight loss (10-25%), comparable to surgery. Newer oral options exist, and these drugs work independently of diabetes status. Consult a doctor to see if you qualify, as they are typically reserved for those who haven't succeeded with lifestyle changes alone.

Retatrutide (LY3437943) administered subcutaneously once weekly produces significant, dose-dependent weight loss and improved glycaemic control in adults with obesity or type 2 diabetes, outperforming placebo and dulaglutide at higher doses (8-12 mg).

Retatrutide is a once-weekly injection that significantly reduces body weight (up to 26 kg in trials) and improves blood sugar control in people with obesity or type 2 diabetes. It works by targeting three hormone receptors (GIP, GLP-1, Glucagon). Higher doses (8-12 mg) are more effective but may cause mild gastrointestinal side effects that usually improve over time. It appears more effective than some existing treatments like dulaglutide for weight loss.

Tirzepatide treatment in patients with obesity and type 1 diabetes results in significant weight loss (median 8.5-12.2%) and reduced insulin requirements without increasing hypoglycemia or serious adverse events.

If you have Type 1 Diabetes and obesity, Tirzepatide is a viable option for weight loss and reducing insulin needs. Start with a low dose (2.5mg) and increase slowly to minimize nausea. You must work with your doctor to adjust your insulin doses to prevent hypoglycemia. Combine the medication with a modest calorie deficit and regular exercise for best results.

Long-term treatment with semaglutide 2.4 mg (up to 68 weeks) produces significant weight loss (mean 14.5-14.8%) and improves cardiometabolic biomarkers (blood pressure, HbA1c, LDL, triglycerides) in real-world patients with obesity or overweight.

If you have obesity or overweight with a related health condition, semaglutide 2.4 mg taken once weekly can lead to significant weight loss (around 15% of body weight) and improvements in blood pressure, blood sugar, and cholesterol over a year. This is based on real-world data from thousands of patients, suggesting it works effectively outside of strict clinical trial settings. You must be willing to stay on the medication for at least a year to see these full benefits.

In overweight or obese adults, tirzepatide produces significantly greater weight loss than semaglutide over a 6-month period, particularly in patients without diabetes.

If you are overweight or obese and considering medication, tirzepatide appears to offer greater weight loss benefits than semaglutide over a 6-month period, especially if you do not have diabetes. However, real-world effectiveness can vary based on adherence and cost, so discuss these factors with your provider.

Combining 16:8 TRE with exercise significantly reduces triglycerides and LDL cholesterol compared to exercise alone, with greater LDL-C reductions observed in men.

If you exercise regularly, adding a 16:8 time-restricted eating schedule may lead to small but significant improvements in triglycerides and LDL cholesterol (bad cholesterol) compared to exercising without dietary timing restrictions. Men may see greater improvements in LDL-C. These benefits are modest and should be viewed as part of a broader cardiometabolic risk-reduction plan.

Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.

If you have obesity and sleep apnea, Tirzepatide has been shown to significantly reduce the severity of your sleep apnea (AHI) and can lead to remission of the condition. This is a unique benefit not clearly demonstrated by other weight loss drugs in this review.

Combining GLP-1 receptor agonists with other Nutrient Stimulated Hormones (NuSH) like glucagon or amylin, or using dual/triple agonists like tirzepatide, may result in less lean mass loss compared to single-agonist GLP-1 treatments.

If you are on semaglutide and worried about muscle loss, ask your doctor if tirzepatide (a dual GLP-1/GIP drug) might be a better option for you, as it appears to spare more muscle. Newer triple-agonist drugs are also in development.

GLP-1 receptor agonists (GLP-1 RA) are associated with significant weight regain after discontinuation, whereas non-GLP-1 related treatments did not show statistically significant regain in this meta-analysis.

If you are on a GLP-1 medication (like semaglutide or liraglutide), stopping it is likely to cause significant weight regain due to the loss of appetite suppression. Other drugs may not show this same statistical pattern of regain in this analysis, but individual responses vary.

Persistent, intrusive, and dysphoric thoughts about food (food noise) are a distinct psychological construct that can be significantly reduced by GLP-1 receptor agonists, leading to improved quality of life and weight management outcomes.

If you experience constant, intrusive, and unpleasant thoughts about food that interfere with your life, this may be 'food noise,' a distinct psychological construct. GLP-1 receptor agonists (like semaglutide) have been shown to significantly reduce this noise, leading to better weight loss outcomes and improved quality of life. This is not a failure of willpower but a treatable condition.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.

If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.

Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.

If you are currently on Liraglutide and struggling with weight or fasting blood sugar, switching to Semaglutide may help you lose more weight and lower your FBS. However, this switch is unlikely to significantly improve your HbA1c levels.